Allogene Therapeutics publishes preclinical data on clinical cancer research supporting DLL3 as a potential AlloCAR T™ target for small cell lung cancer

Allogen Therapeutics, Inc.

SOUTH SAN FRANCISCO, Calif., January 25, 2023 (GLOBE NEWSWIRE) — Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company that pioneered the development of allogeneic CAR T (AlloCAR T™) cancer products, today announced the publication of a preclinical study demonstrating that delta-type ligand 3 (DLL3) is a promising tumor target for AlloCAR T™ in small cell lung cancer (SCLC). The findings were published in Cancer Clinical Researcha journal of the American Association for Cancer Research (AACR).

SCLC is an aggressive disease with limited treatment options. Approximately 30,000 patients in the United States are affected each year with this disease, which has an overall 5-year survival rate of approximately 7%.1 DLL3, with high expression in tumors and limited expression in normal tissue, is a promising target for SCLC and potentially other solid tumors.

“As a leader in allogeneic CAR T research and development, we are committed to exploring the potential of this therapeutic modality across a wide range of indications, including solid tumors where there is a significant need,” said Barbra Sasu, Ph.D., Chief Scientific Officer at Allogene.

This study describes the selection of ALLO-213 as a DLL3-targeted allogeneic T CAR development candidate from a large number of anti-DLL3 CAR candidates based on single-chain variable fragments (scFv). Selection of ALLO-213 was based on potency and specificity against SCLC cell lines in vitro and in vivo, including cell lines with antigen density too low to establish sensitivity. The results of the preclinical study showed:

  • No DLL3 on target toxicity was observed in preclinical models that support a potentially attractive safety profile

  • DLL3 CAR clinical candidates controlled DLL3+ tumor growth in mice lacking normal tissue toxicity

About Allogeneic Therapy
Allogene Therapeutics, headquartered in South San Francisco, is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) products for cancer. Led by a management team with significant experience in cell therapy, Allogene is developing a pipeline of “ready-to-use” CAR T cell candidates with the goal of delivering readily available cell therapy on demand, more reliably and at scale. for more patients. For more information please visit www.allogene.com and follow @AllogeneTx on Twitter and LinkedIn.

Cautionary Note About Forward-Looking Statements
This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The press release may, in some instances, use terms such as “anticipates”, “believes”, “potential” , “proposed”, “continues”, “estimates”, “anticipates”, “expects”, “plans”, “intends”, “may”, “could”, “could”, “will”, “should” or other words that convey uncertainty of future events or results to identify these forward-looking statements. Forward-looking statements include statements about intent, beliefs, projections, perspectives, analysis or current expectations relating to, among other things: the ability to research and develop ALLO-213 or any other AlloCAR T anti-DLL3 candidate; and the potential benefits of any anti-DLL3 AlloCAR T candidate or any other AlloCAR T candidate. A number of factors may cause differences between Allogene’s expectations and actual results, as discussed in more detail in Allogene’s filings with the SEC, including, without limitation, on your Form 8-K filed on November 29, 2022 and under the heading “Risk Factors” of your Form 10-Q for the quarter ended September 30, 2022. Any forward-looking statements made in this press release refer up only as of the date of this press release. Allogene undertakes no obligation to update forward-looking statements, whether as a result of new information, future events or otherwise, after the date of this press release.

AlloCAR T™ is a trademark of Allogene Therapeutics, Inc.

Allogene’s AlloCAR T™ programs utilize Cellectis technologies. The AlloCAR T anti-DLL3 programs are licensed exclusively from Cellectis by Allogene and Allogene owns the global development and commercial rights to these AlloCAR T programs.

Allogene Media/Investor Contact:
Cristina Cassiano
Communications Director
(714) 552-0326
[email protected]

1Lung cancer – small cell – statistics. Cancer.Net. (2023, January 6th). Retrieved January 24, 2023, from https://www.cancer.net/cancer-types/lung-cancer-small cell/stats#:~:text=Lung%20cancer%20is%20the%20second to be%20diagnosed%20with%20lung%20cancer

Allogene Therapeutics publishes preclinical data on clinical cancer research supporting DLL3 as a potential AlloCAR T™ target for small cell lung cancer

Leave a Reply

Your email address will not be published.

Scroll to top